# | Name | Compound Key | Action Type | Relation | Activity Value | Units | Assay ID | Assay Description | Comment | Assay | Assay Organism | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
1. | ALA413 | Rapamycin | t1/2 | = | 40 | hr | ALA5245710 | hr | ||||
2. | ALA413 | Rapamycin | IC50 | = | 0.1 | nM | ALA5245709 | 10.00 | nM | Homo sapiens | ||
3. | ALA413 | Rapamycin | IC50 | = | 0.05 | uM | ALA5223207 | 7.30 | nM | Homo sapiens | ||
4. | ALA413 | Rapamycin | IC50 | = | 1.3 | uM | ALA5216201 | 5.89 | nM | Homo sapiens | ||
5. | ALA413 | Rapamycin | IC50 | = | 4 | uM | ALA5216200 | 5.40 | nM | Homo sapiens | ||
6. | ALA413 | Rapamycin | IC50 | = | 10 | uM | ALA5216199 | 5.00 | nM | |||
7. | ALA413 | Rapamycin | IC50 | = | 2.7 | uM | ALA5216198 | 5.57 | nM | Homo sapiens | ||
8. | ALA413 | Rapamycin | IC50 | = | 0.45 | uM | ALA5216197 | 6.35 | nM | Homo sapiens | ||
9. | ALA413 | Rapamycin | IC50 | = | 49.35 | uM | ALA5216196 | 4.31 | nM | Homo sapiens | ||
10. | ALA413 | Rapamycin | Ki | = | 5.4 | uM | ALA5216195 | 5.27 | nM | Homo sapiens | ||
11. | ALA413 | Rapamycin | solubility | = | 0.003 | mg/ml | ALA5216194 | ug.mL-1 | ||||
12. | ALA413 | Rapamycin | IC50 | = | 0.05 | nM | ALA5216190 | 10.30 | nM | Homo sapiens | ||
13. | ALA413 | Rapamycin | IC50 | = | 0.05 | uM | ALA5137753 | 7.30 | nM | |||
14. | ALA413 | Rapamycin | INH | = | 40 | % | ALA5132025 | % | Middle East respiratory syndrome-related coronavirus | |||
15. | ALA413 | Rapamycin | IC50 | = | 1.9 | uM | ALA5128707 | 5.72 | nM | Homo sapiens | ||
16. | ALA413 | Rapamycin | IC50 | = | 0.05 | nM | ALA4434258 | 10.30 | nM | Mus musculus | ||
17. | ALA413 | Rapamycin | Activity | 0 | ALA4425450 | Active | Homo sapiens | |||||
18. | ALA413 | Rapamycin | Activity | 0 | ALA4413671 | Non-Toxic | ||||||
19. | ALA413 | Rapamycin | TGI | = | 73.8 | % | ALA4413665 | % | Homo sapiens | |||
20. | ALA413 | Rapamycin | INH | 0 | ALA4413656 | Active | % | Homo sapiens |